
metro-minnesota

MMCORC



community oncology research consortium

Bringing the advantages of cancer research to the community

Maureen Fusselman, RN, MS, CCRP
Program Manager – NCI Treatment Trials


MMCORC

The Metro-Minnesota Community Oncology Research Consortium (MMCORC) is a nonprofit research program sponsored by the National Cancer Institute (NCI) and participating hospitals and clinics. Local physicians have access to the newest advances in cancer research. The MMCORC links community cancer specialists, primary care physicians and other health care professionals to NCI-approved clinical trials.

This program gives people in our community access to:

- the newest therapies available for cancer treatment
- management of treatment side effects and disease symptoms
- studies directed at cancer prevention
- molecular-based precision medicine research
- cancer care delivery research

Physicians & staff located in 25 hospitals and clinics in Minneapolis-St. Paul, MN and the surrounding suburbs; Stillwater, MN; Willmar, MN; New Ulm, MN; and New Richmond, WI; including most of the Minnesota Oncology clinics.



Abbott Northwestern Hospital • Minnesota Oncology - Minneapolis

Cambridge Medical Center

Fairview Lakes

Fairview Maple Grove

Fairview Northland Medical Center

Fairview Ridges Hospital • Minnesota Oncology - Burnsville

Fairview Southdale Hospital • Minnesota Oncology - Edina

Health Partners Riverside Clinic

Hennepin County Medical Center

Lakeview Hospital (Stillwater)

Mercy Hospital • Minnesota Oncology – Coon Rapids

Mercy Unity Campus • Minnesota Oncology - Fridley

Minnesota Oncology - Maplewood Cancer Center

Minnesota Oncology - Woodbury Clinic

Monticello Cancer Center

New Ulm Medical Center

North Memorial Health Care

Park Nicollet Health Services

Regions Hospital

Rice Memorial Hospital (Willmar)

Ridgeview Medical Center • Minnesota Oncology - Waconia

St. Francis Regional Medical Center

St. John's Hospital HealthEast

United Hospital • Minnesota Oncology – St Paul

Westfields Hospital (Wisconsin)

BOLD = GYN clinics

metro-minnesota

MMCORC

community oncology research consortium



NATIONAL CANCER INSTITUTE
Community Oncology
Research Program (NCORP)

- » **25**
consortium member sites
- » **50+**
employees
- » **110**
cancer clinical trials for patient enrollment
- » **180**
local investigators
- » **650+**
patients onto national clinical
trials per year

MMCORC Cancer Clinical Trial portfolio

Treatment	adjuvant treatment & advanced disease
Cancer Control	symptom management & cancer prevention
Cancer Care Delivery	evidenced-based practice change that improves clinical outcomes, patient experiences & optimizes value (Financial impact)
Industry	access to newest therapies available

NRG
ONCOLOGY


Advancing Research. Improving Lives.™



GOG® FOUNDATION, INC.



NCI Treatment Trials



NRG Oncology brings together the unique and complementary research areas of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the **Gynecologic Oncology Group (GOG)**.

NRG - GY007 A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

- Stage III or IV ovarian cancer patients who will receive neoadjuvant chemotherapy with interval tumor reductive surgery
- Open to enrollment: Phase II currently
- 2 Treatment assignment groups:
 - Paclitaxel + Carboplatin
 - Paclitaxel + Carboplatin + Ruxolitinib (an oral JAK inhibitor)

NRG - GY005 A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

- Platinum-resistant or platinum-refractory recurrent ovarian cancer patients
- Open to enrollment: Phase III currently
- 3 Treatment assignment groups:
 - Cediranib (VEGF inhibitor)
 - Cediranib + Olaparib (PARP inhibitor)
 - Non-platinum based standard chemo

NRG - CC004 Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer

- Cancer Control trial for breast and GYN cancer patients with decreased sexual desire at least 6 months following cancer treatment
- Open to enrollment: Phase II currently
- 3 Treatment assignment groups:
 - Bupropion 150 mg
 - Bupropion 300 mg
 - Placebo (can cross-over to treatment after 10 weeks)

MNCCTN004: Nasal Vestibulitis Natural History Evaluation

- Symptom Management study for patients initiating chemotherapy
- Open to enrollment at Monticello only
- Questionnaires during 4 months of chemo to evaluate unpleasant nasal symptoms that might be side effect of study treatment containing:
 - Paclitaxel
 - Docetaxel
 - Nab-paclitaxel
 - Bevacizumab
 - Other chemotherapy

Industry: GOG3020 ATHENA A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-line Platinum-based Chemotherapy

- Newly diagnosed advanced high-grade epithelial ovarian cancer patients who have completed platinum-based chemo and surgery with no evidence of disease
- Open to enrollment: Phase III
- 4 Treatment assignment groups: (4:4:1:1 allocation)
 - Rucaparib (PARP inhibitor) + nivolumab (immunotherapy)
 - Rucaparib + placebo
 - placebo + nivolumab
 - Placebo + placebo

NRG - GY019 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

- Newly diagnosed Stage II-IV low-grade serous ovarian cancer patients following cytoreductive surgery
- Will be opening to enrollment soon: Phase III
- 2 Treatment assignment groups:
 - Paclitaxel + Carboplatin + Letrozole (enzyme inhibitor)
 - Letrozole

NRG - GY009 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

- platinum-resistant recurrent ovarian cancer patients
- Currently suspended to analyze Phase II results
- 3 Treatment assignment groups:
 - Pegylated Liposomal Doxorubicin + Atezolizumab
 - Pegylated Liposomal Doxorubicin + Bevacizumab + Atezolizumab (immunotherapy)
 - Pegylated Liposomal Doxorubicin + Bevacizumab

ECOG-ACRIN EAE161 Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma

- Platinum-resistant recurrent or persistent epithelial ovarian cancer patients
- Currently suspended to revise study design
- Perfusion CT before and after bevacizumab + paclitaxel to predict outcomes

NRG - GY016 A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary

- Recurrent clear cell ovarian cancer patients
- Currently suspended for interim analysis
- Pembrolizumab (immunotherapy) + Epacadostat (enzyme inhibitor)

NRG - GY014 A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

- platinum-resistant recurrent or persistent ovarian endometrioid or clear cell cancer patients
- Currently suspended to analyze stage 1 results
- Tazemetostat (selectively inhibits intracellular H3K27 methylation)



Better Together

Bringing the advantages of cancer research to the community

The Metro-Minnesota Community Oncology Research Consortium (MMCORC) is a nonprofit research consortium of 22 local hospitals and clinics, which provides people in our community access to the newest therapies available for cancer treatment and prevention through national cancer clinical trials.



OUR MISSION

Bringing the advantages of cancer research to the community



NEWS

- MMCORC Press Release
- Cancer Care Delivery Research (CCDR) Program Bulletin
- MMCORC Brochure



RESOURCES

Are you looking for help? We have a range of resources that are available to you to help get the information you need fast!



REFERRALS

If you are a referring physician or a patient looking to enroll into a clinical trial, contact us at

952-993-1517.